The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO GI 2024 | Artificial intelligence for detecting hepatocellular carcinoma
Hepatocellular carcinoma (HCC) is often diagnosed late, limiting treatment options to palliative care due to disease progression. Lorenza Rimassa, MD, IRCCS Humanitas Research Hospital, Milan, Italy, highlights findings from a retrospective study, which demonstrated that an artificial intelligence (AI) signature was able to anticipate the diagnosis of HCC earlier. However, these findings need confirmation in larger, diverse, and prospective patient cohorts. This interview took place at 2024 European Society for Medical Oncology (ESMO) Gastrointestinal Cancer Annual Congress in Munich, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
